查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587459

美國臨床腫瘤學次世代定序市場規模、佔有率、趨勢分析報告：按工作流程、按技術、按應用、按最終用途、細分市場預測，2025-2030 年

U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國臨床腫瘤學次世代定序儀市場成長與趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，美國臨床腫瘤新一代定序市場規模將達到5.04億美元，2025年至2030年複合年成長率為15.04%。

由於行業參與者之間的競爭加劇、該領域的技術進步以及基因序列測定成本的降低，預計該市場在 2023-2030 年預測期內將出現顯著成長。

日益激烈的市場競爭以及腫瘤學領域次世代定序儀推出的創新解決方案預計將在預測期內推動市場成長。例如，2023年2月，癌症篩檢和診斷測試公司Exact Sciences Corp.在美國宣布了其治療選擇測試—OncoExTra。這是一種基於定序的下一代基因組測試，可以幫助癌症治療。幫助理解和表徵癌症腫瘤。此外，各公司正在共同努力，重點關注次世代定序的進步，以獲得該行業的競爭優勢。例如， 次世代定序的潛力。

此外，也發表了有關次世代定序在腫瘤學和癌症治療中的應用的各種論文和研究。例如，2023 年 6 月，《刺胳針》發表了一篇關於癌症患者次世代定序測試的真實結果和效用的論文。此外，2023 年 6 月，美國臨床腫瘤學會發表了一項關於次世代定序測試對美國晚期癌症管理的臨床影響的研究。此類研究正在幫助研究人員和臨床醫生提高對次世代定序在癌症治療中的應用的認知和知識。

此外，由於定序成本的降低，預計預測期內臨床腫瘤學次世代定序市場的成長將會成長。透過增加平行定序和運作多個流動槽以提高定序容量，可以降低次世代定序的成本，而不會增加相關成本。預計這些因素將在預測期內增加美國的市場需求。

美國臨床腫瘤學下一代定序市場報告亮點

  • 依工作流程細分，次世代定序在 2024 年的銷售額佔有率最大，為 56.65%。該領域的主導地位是由於該領域的癌症測序計劃數量不斷增加和技術進步。
  • 從技術來看，標靶定序和定序佔據市場主導地位，2024年收益佔有率為72.51%。這是由於擴大使用標靶化組合及其在識別癌症腫瘤方面的效率。
  • 從應用來看，篩檢領域在美國臨床腫瘤次世代定序市場佔據主導地位，2024年收益佔有率為79.94%。
  • 依最終用途分類，2024年實驗室細分市場在美國臨床腫瘤次世代定序市場中佔據最大佔有率，為63.47%。該領域的主導地位是由於癌症治療的研發活動不斷增加。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國臨床腫瘤學次世代定序市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章美國臨床腫瘤學次世代定序市場：技術估算與趨勢分析

  • 技術細分儀表板
  • 美國臨床腫瘤次世代定序市場技術波動分析
  • 2018-2030年美國臨床腫瘤學次世代定序市場規模及趨勢分析（依技術）
  • 全基因測序
    • 全基因測序市場，2018-2030
  • 全EXOME定序
    • 全EXOME定序市場，2018-2030
  • 標靶定序和定序
    • 2018-2030 年標靶定序與定序市場

第5章美國臨床腫瘤學次世代定序市場：依工作流程進行估計與趨勢分析

  • 工作流程細分儀表板
  • 美國臨床腫瘤次世代定序市場工作流程變化分析
  • 2018-2030年美國臨床腫瘤學次世代定序市場規模與趨勢分析（依工作流程）
  • 次世代定序預測序
    • 次世代定序定序序市場，2018-2030
  • 次世代定序定序
    • 次世代定序定序市場，2018-2030
  • 次世代定序資料分析
    • 次世代定序資料分析市場，2018-2030

第6章美國臨床腫瘤次世代定序市場：按應用、估計和趨勢分析

  • 使用細分儀表板
  • 美國臨床腫瘤次世代定序市場應用變化分析
  • 2018-2030年美國臨床腫瘤次世代定序市場規模及趨勢分析（依應用）
  • 篩檢
    • 篩檢市場，2018-2030
    • 散發性癌症
    • 遺傳性癌症
  • 伴同性診斷
    • 伴同性診斷市場，2018-2030
  • 其他
    • 其他市場，2018-2030

第7章美國臨床腫瘤學次世代定序市場：最終用途的估計和趨勢分析

  • 最終用途細分儀表板
  • 美國臨床腫瘤次世代定序市場的最終用途變異分析
  • 2018-2030 年按最終用途分類的市場規模和趨勢分析
  • 醫院
    • 醫院市場，2018-2030
  • 診所
    • 診所市場，2018-2030
  • 研究所
    • 實驗室市場，2018-2030

第8章 競爭格局

  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Myriad Genetics, Inc.
    • Beijing Genomics Institute（BGI）
    • QIAGEN
    • Perkin Elmer, Inc.
    • PacBio
    • Oxford Nanopore Technologies
    • PerkinElmer Inc
    • Macrogen, Inc
Product Code: GVR-1-68038-168-9

U.S. Clinical Oncology Next Generation Sequencing Market Growth & Trends:

The U.S. clinical oncology next-generation sequencing market size is expected to reach USD 500.4 million by 2030, expanding at a CAGR of 15.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is expected to increase at a significant rate during the forecast period from 2023 to 2030 owing to the increasing competition among the industry players, technological advances in the field and decreasing costs for genetic sequencing.

The increasing market competition and the launch of innovative solutions based on next generation sequencing in the oncology field are expected to fuel market growth over the forecast period. For instance, in February 2023, Exact Sciences Corp., a cancer screening and diagnostic testing company, introduced the therapy selection test -OncoExTra in the U.S. It is a next-generation sequencing-based genomic test to help in cancer care. It helps in understanding and characterizing cancer tumors. Moreover, to gain a competitive edge in the industry, companies are collaborating and focusing on advancing in the next generation sequencing. For instance, in January 2020, the two key players operating in the market, Illumina, Inc and F. Hoffmann-La Roche Ltd, signed a 15-year agreement to discover NGS's potential to transform cancer detection, diagnosis, risk prediction, treatment, and monitoring.

Moreover, various articles and studies are being published on the use of NGS in oncology and cancer treatments. For instance, in June 2023, the Lancet published an article on real-world outcomes and the usefulness of NGS testing in cancer patients. Furthermore, in June 2023, the American Society Of Clinical Oncology published a study on the clinical impact of NGS tests for managing advanced cancer in the U.S. Such studies help researchers and clinicians increase awareness and knowledge about the use of NGS for cancer treatments.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is expected to witness growth due to reduced sequencing costs. The costs of NGS can be reduced by increasing parallel sequencing and running multiple flow cells to increase sequencing capacity without raising the costs associated with it. These factors are anticipated to boost the market demand over the forecast period in the U.S.

U.S. Clinical Oncology Next Generation Sequencing Market Report Highlights:

  • NGS sequencing accounted for the largest revenue share of 56.65% in 2024 based on the workflow segment. The dominance of the segments is due to the increasing number of cancer sequencing projects and technological advances in the field.
  • Based on the technology, targeted sequencing & resequencing dominated the market with a revenue share of 72.51% in 2024. This can be attributed to the rising use of targeted panels and their efficiency in identifying cancer tumors.
  • Based on the application, the screening segment dominated the U.S. clinical oncology NGS market with a revenue share of 79.94% in 2024, owing to the growing prevalence of cancer disorder across the country.
  • Based on the end-use, the laboratories segment accounted for the largest share of 63.47% in the U.S. clinical oncology NGS market in 2024. This dominance of the segment is due to the rising research and development activities for cancer treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Technology
    • 1.2.2. Workflow
    • 1.2.3. Application
    • 1.2.4. End Use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Reduction in costs for genetic sequencing
      • 3.2.1.2. Advances in the field of personalized medicine
      • 3.2.1.3. Increase in prevalence of cancer
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Lack of computational efficiency for data management
  • 3.3. U.S. Clinical Oncology NGS Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Segment Dashboard
  • 4.2. U.S. Clinical Oncology NGS Market Technology Movement Analysis
  • 4.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
  • 4.4. Whole Genome Sequencing
    • 4.4.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 4.5. Whole Exome Sequencing
    • 4.5.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
  • 4.6. Targeted Sequencing & Resequencing
    • 4.6.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market: Workflow Estimates & Trend Analysis

  • 5.1. Workflow Segment Dashboard
  • 5.2. U.S. Clinical Oncology NGS Market Workflow Movement Analysis
  • 5.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
  • 5.4. NGS Pre-Sequencing
    • 5.4.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
  • 5.5. NGS Sequencing
    • 5.5.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
  • 5.6. NGS Data Analysis
    • 5.6.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. U.S. Clinical Oncology NGS Market Application Movement Analysis
  • 6.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Screening
    • 6.4.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.4.2. Sporadic Cancer
      • 6.4.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market ,2018 - 2030 (USD Million)
    • 6.4.3. Inherited cancer
      • 6.4.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market ,2018 - 2030 (USD Million)
  • 6.5. Companion Diagnostics
    • 6.5.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.6. Other Diagnostics
    • 6.6.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market: End Use Estimates & Trend Analysis

  • 7.1. End Use Segment Dashboard
  • 7.2. U.S. Clinical Oncology NGS Market End Use Movement Analysis
  • 7.3. U.S. Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 7.4. Hospitals
    • 7.4.1. Hospitals U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.5. Clinics
    • 7.5.1. Clinics U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.6. Laboratories
    • 7.6.1. Laboratories U.S. Clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Illumina, Inc.
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. F. Hoffmann-La Roche Ltd
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Agilent Technologies, Inc.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Myriad Genetics, Inc.
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Beijing Genomics Institute (BGI)
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. QIAGEN
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Perkin Elmer, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. PacBio
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. Oxford Nanopore Technologies
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives
    • 8.3.11. PerkinElmer Inc
      • 8.3.11.1. Overview
      • 8.3.11.2. Financial Performance
      • 8.3.11.3. Product Benchmarking
      • 8.3.11.4. Strategic Initiatives
    • 8.3.12. Macrogen, Inc
      • 8.3.12.1. Overview
      • 8.3.12.2. Financial Performance
      • 8.3.12.3. Product Benchmarking
      • 8.3.12.4. Strategic Initiatives

List of Tables

  • TABLE 1 Cancer Incidence and Mortality, 2018
  • TABLE 2 U.S. clinical Oncology NGS Market estimates & forecasts
  • TABLE 3 U.S. clinical Oncology NGS Market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • TABLE 4 U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • TABLE 5 U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 6 U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Market snapshot
  • FIG. 2 Market research process
  • FIG. 3 Information procurement
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Market trends & outlook
  • FIG. 7 Market segmentation & scope
  • FIG. 8 Market driver relevance analysis (Current & future impact)
  • FIG. 9 Market restraint relevance analysis (Current & future impact)
  • FIG. 10 PESTLE Analysis
  • FIG. 11 Porter's Five Forces Analysis
  • FIG. 12 Strategy framework
  • FIG. 13 Participant categorization
  • FIG. 14 U.S. clinical oncology NGS market: Technology outlook key takeaways
  • FIG. 15 U.S. clinical oncology NGS market: Technology movement analysis
  • FIG. 16 Whole genome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • FIG. 17 Whole exome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • FIG. 18 Targeted sequencing and resequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • FIG. 19 U.S. clinical oncology NGS market: Workflow outlook key takeaways
  • FIG. 20 U.S. clinical oncology NGS market: Workflow movement analysis
  • FIG. 21 NGS pre-sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • FIG. 22 NGS sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • FIG. 23 NGS data analysis for U.S. clinical oncology market, 2018 - 2030 (USD Million)
  • FIG. 24 U.S. clinical oncology NGS market: Application outlook key takeaways
  • FIG. 25 U.S. clinical oncology NGS market: Application movement analysis
  • FIG. 26 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • FIG. 27 Sporadic cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • FIG. 28 Inherited cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • FIG. 29 Companion diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • FIG. 30 Other diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • FIG. 31 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • FIG. 32 Key companies profiled